A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

NCT05316220 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped strategic considerations

Conditions

Ulcerative Colitis (UC)

Interventions

DRUG: Mesalamine
DRUG: Placebo

Sponsor

AbbVie